image credit: Adobe Stock

Yposkesi Launches LentiSure Lentiviral Vector Production Platform

Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, launched LentiSure, an optimized Lentiviral (LV) Vector manufacturing platform for increasing lentivirus production efficiency and robustness. Lentivirus or LV vectors are used to produce cell-based immuno-oncology therapies. Their robustness as a gene delivery system is vital in determining the success of any cell-based cancer treatment.

LentiSure’s capabilities in producing LV vectors with consistent product quality, the overall average titers at cell culture harvest is at 10e7 IG/mL bioreactor volume, offer cell therapy developers the assurance of higher productivity and a higher probability of achieving the desired outcomes.

Read More on Contract Pharma